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INTRODUCTION
Community-acquired pneumonia (CAP) is one of the most
common respiratory diseases in children and it represents a
frequent cause of hospital admission. Streptococcus pneumoniae
is the leading cause of CAP in children aged 3 weeks to 5 yr,
and it is the major pathogen leading to complicated pneumo-
nia such as parapneumonic effusion and empyema (1). Pleu-
ral effusion occasionally develops in children with commu-
nity-acquired bacterial pneumonia and this can be diagnosed
in about 40-50% of patients with bacterial pneumonia (2).
S. pneumoniae is the leading etiologic agent associated with
parapneumonic effusions in the children for whom an etio-
logic agent was recovered. Despite of its prevalence, there is
only limited consensus about its pathogenesis due to the lack
of available evidence-based data. Increased vascular perme-
ability and leakage may play an important role in the devel-
opment of exudative pleural effusions.
Vascular endothelial growth factor (VEGF) is a dimeric
46-kDa protein, and it is an endothelial, cell-specific, multi-
functional cytokine that plays an important role in angiogen-
esis and vascular permeability (3-5). VEGF has been postu-
lated to be an important mediator in the formation of malig-
nant pleural and peritoneal fluid (6). VEGF levels are also
known to be elevated in chronic pulmonary diseases such as
asthma and cystic fibrosis (7-9). It has recently been report-
ed that serum VEGF levels are significantly increased in the
patients with active pulmonary tuberculosis and these levels
are decreased after successful treatment (10). However in regard
to pneumonia, only a few cases have been reported on so far
(11, 12), and there has been no data about CAP as classified
on the basis of the radiologic type and etiology. Therefore,
we investigated the serum levels of VEGF in pediatric patients
with CAP according to its radiologic type and etiology to
see if the serum VEGF levels are related to the pathogenesis
of severe, complicated pneumonia. 
MATERIALS AND METHODS 
Study groups
From 1 May 2003 to 30 June 2004, 29 children with CAP
(11 boys and 18 girls aged from 4 to 168 months; mean age:
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Serum Vascular Endothelial Growth Factor in Pediatric Patients with
Community-Acquired Pneumonia and Pleural Effusion
This study investigated the serum vascular endothelial growth factor (VEGF) levels
in children with community-acquired pneumonia. Serum VEGF levels were mea-
sured in patients with pneumonia (n=29) and in control subjects (n=27) by a sand-
wich enzyme-linked immunosorbent assay. The pneumonia group was classified
into bronchopneumonia with pleural effusion (n=1), bronchopneumonia without
pleural effusion (n=15), lobar pneumonia with pleural effusion (n=4), and lobar
pneumonia without pleural effusion (n=9) groups based on the findings of chest
radiographs. We also measured serum IL-6 levels and the other acute inflamma-
tory parameters. Serum levels of VEGF in children with pneumonia were signifi-
cantly higher than those in control subjects (p<0.01). Children with lobar pneumo-
nia with or without effusion showed significantly higher levels of serum VEGF than
children with bronchopneumonia. For lobar pneumonia, children with pleural effu-
sion showed higher levels of VEGF than those without pleural effusion. Children with
a positive urinary S. pneumonia antigen test also showed higher levels of VEGF
than those with a negative result. Serum IL-6 levels did not show significant differ-
ences between children with pneumonia and control subjects. Serum levels of
VEGF showed a positive correlation with the erythrocyte sedimentation rate in the
children with pneumonia. In conclusion, VEGF may be one of the key mediators
that lead to lobar pneumonia and parapneumonic effusion.
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52 months) and 27 afebrile healthy children were prospecti-
vely recruited for this study. The children with CAP had acute
respiratory symptoms with fever (temperature ≥38.0℃) and
new infiltrates on their chest radiographs. Patients were ex-
cluded from the study if any of the following criteria were
found: the presence of malignancy, immunodeficiency or con-
gestive heart disease; the presence of an alternative diagnosis
during the follow-up; the children had been hospitalized in
the preceding 72 hr. 
Parapneumonic effusion was evaluated with chest radio-
graphs and the patient was excluded from the study if the
cause of the patient’s illness was identified as other than pneu-
monia, or if the pleural fluid was transudate. The patients
were classified into bronchopneumonia with pleural effusion
(n=1), bronchopneumonia without pleural effusion (n=15),
lobar pneumonia (focal consolidation was considered as lobar
pneumonia) with pleural effusion (n=4), and lobar pneumo-
nia without pleural effusion (n=9). Twenty seven healthy
children who visited hospital for routine checks and had no
respiratory symptoms were enrolled as the control group (13
boys and 14 girls; age range: 80-132 months; mean age: 119
months). The study design was approved by the ethics com-
mittee of the hospital and an informed consent was obtained
from all the parents.
Microbiological investigations
To identify the causative organisms, we performed blood
and/or pleural fluid culture, rapid urinary Streptococcal pneu-
moniae antigen test and detection of antibody to Mycoplasma
pneumoniae. Pleural fluid was obtained by thoracentesis from
the patients with parapneumonic effusion. Pleural fluid was
investigated for biochemistry, the leukocyte count, Gram’s
stain and culture for aerobic and anaerobic bacteria. Exudate
was defined by the ratio of the protein in pleural fluid/serum
>0.5 and the ratio of LDH in the pleural fluid/serum >0.6.
We did not perform culture, polymerase chain reaction or
serologic investigations for virus.
The urine samples were analysed for the presence of S. pneu-
moniae cell-wall antigen with using the rapid urine S. pneumo-
niae antigen assay kit (Binax NOW
�, Portland, ME, U.S.A.).
This test device contains an immunochromatographic mem-
brane that is used to detect soluble pneumococcal antigen
in human urine. Blood samples were drawn on days 1 and
14 of treatment for the detection of antibodies to Mycoplas-
ma pneumoniae, and the infection was defined as mycoplasma
pneumonia when a fourfold increase of the antibody titer was
detected during the convalescent period.
Measurement of VEGF and IL-6 
On the first day of admission, venous blood was drawn and
centrifuged at 300×g for 10 min at 4℃. The samples were
stored at -70℃until the measurements of VEGF and IL-6
were performed with using enzyme linked immunosorbent
assay kits (R&D Systems, Minneapolis, MN, U.S.A.).
In brief, 200  L of the cell supernatant was incubated with
50  L of assay diluent for 2 hr at room temperature in a 96-
well plate coated with a monoclonal antibody against VEGF
or IL-6. After three washes, a conjugate that consisted of a
polyclonal VEGF or IL-6 antibody and horseradish peroxidase
was then added, and this was allowed to incubate for 2 hr at
room temperature. After addition of a color reagent, the absor-
bance was measured at a wavelength of 450 nm in a Ther-
mo-Max microplate reader. For standardization, serial dilu-
tions of recombinant human VEGF or IL-6 were assayed at
the same time. The detection limit was 3.12 pg/mL for IL-6
and 31.2 pg/mL for VEGF. 
Tests for the complete blood cell count, the erythrocyte sed-
imentation rate (ESR), and the C-reactive protein (CRP) lev-
els were performed at the same time.
Statistical analysis 
The results were expressed as means±standard error of the
mean. All the statistics were performed by using the SPSS
version 11.0 software program. Comparison of the VEGF and
IL-6 concentrations between the study groups were analyzed
by the Mann-Whitney rank sum test and p values <0.05 were
considered as significant. The correlations were determined
by Spearman rank correlation test. 
RESULTS 
Patient characteristics
The characteristics of the enrolled children are presented
in Table 1. Out of the 29 children with pneumonia, there
were 16 children with bronchopneumonia (1 with parapneu-
monic effusion) and 13 children with lobar pneumonia (4 with
parapneumonic effusion). Thoracentesis was performed in 4
patients with parapneumonic effusion except for one patient
with bronchopneumonia who had only a scanty amount of
fluid. All the pleural fluids were confirmed as exudates.
The mean age of the control group was higher compared
to the pneumonia groups. However, age did not influence
the serum VEGF concentrations. Neither our previous study
(13) nor this study showed any correlations between serum
VEGF levels and the subjects’ age in control groups. The
mean white blood cell counts in the patients with pneumo-
nia were higher than those in the control subjects, but showed
no differences among the pneumonia groups. The mean level
of C-reactive protein was significantly increased in the patients
having lobar pneumonia with effusion compared to the pati-
ents having lobar pneumonia without effusion and the patients
having bronchopneumonia with effusion. The mean erythro-
cyte sedimentation rate was significantly increased in the610 S.H. Choi, E.Y. Park, H.L. Jung, et al.
patients having lobar pneumonia with effusion compared to
the other groups, and the ESR was also significantly increased
in the patients having lobar pneumonia without effusion com-
pared to the patients having bronchopneumonia with effusion.
The urinary Streptococcus pneumoniae antigen test was positive
in 5 of 13 patients with lobar pneumonia, and this test was
negative in all the patients with bronchopneumonia. Among
those five patients with positive tests, three patients had para-
pneumonic effusions. There were no culture-confirmed cases.
There were 8 patients with mycoplasma pneumonia. Four
of them had bronchopneumonia and two patients had lobar
pneumonia without effusion and two patients had lobar pne-
umonia with effusion. The serum levels of IL-6 showed no
significant differences among the pneumonia groups.
Serum VEGF and IL-6 levels according to the radiologic
types of pneumonia and the etiologies
The mean concentration of serum VEGF was 669.42±
85.28 pg/mL in the patients with pneumonia, and this was
significantly increased compared to the control subjects (110.23
±4.77 pg/mL, p<0.01). The mean level of serum VEGF in
the patients with lobar pneumonia was 987.95±133.10 pg/
mL, and this was significantly higher than that in the patients
with bronchopneumonia (410.62±55.96 pg/mL, p<0.01)
(Fig. 1). 
In the patients with lobar pneumonia, the serum VEGF
levels of those with pleural effusion (1432.48±242.94 pg/
mL) were also significantly higher than in those patients
without pleural effusion (790.37±122.63 pg/mL, p=0.021).
Likewise, in the patients with lobar pneumonia, the mean
level of serum VEGF in those patients with a positive urine
S. pneumoniae antigen test (1153.73±95.35 pg/mL) was
significantly increased compared to those patients with neg-
ative results (702.06±172.15 pg/mL, p=0.047) (Fig. 2). For
the patients with mycoplasma pneumonia, they did not show
any significant differences in the serum VEGF and IL-6 levels
compared to those patients without mycoplasma pneumonia
Bronchopneumonia
Pleural effusion (+) Pleural effusion (-)
Control
Lobar pneumonia
Pleural effusion (+) Pleural effusion (-)
Number 1 15 4 9 27
Age (months, mean±SD) 36* 44±7* 37±23* 67±10* 119±7
Pneumococcal Antigen (+)
�(%) 0 (0%) 0 (0%)  3 (75%) 2 (22.2%) N.D
Mycoplasmal pneumonia (%) 0 (0%) 4 (26.7%)  2 (50%) 2 (22.2%) N.D
WBC (/ L) 22,260* 14,529±2,406* 13,482±2317* 12,654±3,326* 6,505±282
CRP (mg/dL) 19 9.10±0.55 18.10±4.14
� 8.45±2.36 N.D
ESR (mm/hr) N.D 19.91±2.60 44.5±2.12
� 30.25±8.26 N.D
VEGF (pg/mL) 777.74* 386.15±53.79* 1432.48±242.94* 790.37±122.63* 110.23±4.77
IL-6 (pg/mL) 3.35 70.86±18.89 80.68±27.58 76.30±28.70 N.D
Table 1. Patient profiles and laboratory findings in each group 
Data are presented as mean±SEM. N.D, Not done.
*p<0.05 compared with control group; 
�
Urine streptococcal pneumonia antigen test positive; 
�
p<0.05 compared with lobar pneumonia, and broncho-
pneumonia without pleural effusion group; 
�
p<0.05 compared with bronchopneumonia without pleural effusion group.
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Fig. 1. (A) Comparison of the serum VEGF concentrations between the pneumonia and control groups. Serum concentrations of VEGF in
the children with pneumonia are much higher than those VEGF levels in the control subjects (p<0.01). (B) Comparison of the serum VEGF
concentrations according to the types of pneumonia on the basis of the chest radiographs. The serum levels of VEGF in children with lobar
pneumonia are significantly higher than those VEGF levels in the children with bronchopneumonia (p<0.01).
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(data not shown). 
For the serum IL-6 levels, there were no significant differ-
ences between the patients with bronchopneumonia and
lobar pneumonia, and between the patients with effusion
and without effusion, and nor were there significant differ-
ences between the subjects who were positive or negative on
the urinary S. pneumoniae antigen test (data not shown). The
serum levels of VEGF in the patients with pneumonia showed
positive correlation with their erythrocyte sedimentation rates
(p=0.024), but there was no correlation with the serum IL-6
and CRP levels (Fig. 3). The white blood cell counts and the
duration of fever showed no correlations with the serum VEGF
levels (data not shown).
DISCUSSION
In this study, we have demonstrated that the serum VEGF
concentrations were elevated in the children with pneumonia,
and especially in those children who had lobar pneumonia
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Fig. 2. Comparison of the serum VEGF concentrations between
the children with and without pleural effusion (A), and between
the children with positive and negative urinary S. pneumoniae
antigen tests (B) in the lobar pneumonia group. The serum levels
of VEGF in the children with pleural effusion and a positive urinary
S. pneumoniae antigen test are significantly higher than those with-
out pleural effusion and a negative urinary S. pneumoniae antigen
test (p<0.05). 
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Fig. 3. Correlation of the serum VEGF concentrations with the acute
inflammatory parameters. (A) Serum levels of VEGF in the children
with pneumonia show positive correlation with the erythrocyte sed-
imentation rate (ESR). (B, C) Serum levels of IL-6 and C-reactive
protein (CRP) show no significant correlations with the serum VEGF
levels.
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and parapneumonic effusion. This may reflect that an acute
lower respiratory tract infection can increase the production
and release of VEGF. VEGF is known to be elevated in chronic
lung diseases such as asthma and cystic fibrosis (7, 8, 14, 15),
whereas there are little data on its relationship with acute
pneumonia (11), and furthermore, there is no data on CAP.
In a study on acute eosinophilic pneumonia, the VEGF lev-
els were measured in the bronchoalveolar lavage (BAL) fluids
and its levels in the patients with acute eosinophilic pneu-
monia were higher than those VEGF levels of the control
group, and the VEGF levels rapidly decreased to the control
levels in parallel with the clinical improvement (11). Another
clinical study showed that the serum VEGF levels were ele-
vated in cystic fibrosis patients having acute exacerbations,
and these levels were decreased with antibiotic therapy (14).
These data support our results showing that the VEGF ele-
vation is related to the airway inflammation associated with
infection. On the contrary, in a study using lung autopsy mate-
rial from septic patients, it was demonstrated that the pul-
monary VEGF expression was decreased in the septic patients
compared to that in the controls (16). Even though pneumo-
nia, pulmonary edema and acute respiratory distress syndrome
are the usual pulmonary manifestations during sepsis, the
postmortem lung tissue seems to be different from the lung
tissue seen in the acute infection states, and other factors such
as mechanical ventilation, prolonged antibiotic use and a
downhill clinical course to death will contribute to the con-
founding variables.
There have been no data that the serum VEGF level is relat-
ed to the radiologic type of pneumonia. In this study, the serum
levels of VEGF were higher in the patients with lobar pneu-
monia than in those patients with bronchopneumonia. It is
not certain whether the VEGF elevation is related to the extent
of inflammation or if it is related to the virulence of the mic-
roorganisms. In an in vitro study, Staphylococcus aureus stimu-
lated VEGF release from the normal mesothelial cells in a
dose-dependent and time-dependent pattern (17), and Strepto-
coccus pneumoniae induced the dose- and time-dependent secre-
tion of VEGF from human neutrophils (18). S. aureus and S.
pneumoniae are two of the most common causes of severe, com-
plicated pneumonia with parapneumonic effusion and empye-
ma. There was no data on the association of the VEGF release
with adenovirus infection, which can cause complicated pneu-
monia that mimics bacterial pneumonia (19). 
In our study, the children with a positive urinary S. pneu-
moniae antigen test showed higher levels of serum VEGF than
those children with negative results for lobar pneumonia. We
found that all the cases with positive urinary pneumococcal
antigen tests were lobar pneumonia with or without parap-
neumonic effusion; and no bronchopneumonia cases were pos-
itive on this test. Even though the urinary S. pneumoniae anti-
gen test alone cannot be a tool for the definitive diagnosis of
pneumococcal infection, it can be used as a presumptive diag-
nostic method, especially in case of invasive pneumococcal
infection (whether it is bacteremia or lobar pneumonia). S.
pneumoniae is isolated from the blood or pleural fluid in only
10-30% of pneumococcal pneumonia patients. The urinary S.
pneumoniae antigen test yields a sensitivity of 77-92% and a
specificity of 97-100% (20-23). 
The level of VEGF has been shown to be consistently higher
in the exudative pleural effusions than in the transudative
pleural effusions (17, 24-26). The empyema fluids also con-
tain high levels of VEGF (24, 27), which is up to five fold
higher than the VEGF levels in the uncomplicated parapneu-
monic effusions (17). This study suggests that more compli-
cated pneumonia which is usually caused by more virulent
pathogens seems to be associated with a greater release of
VEGF. 
We did not compare the serum VEGF levels with those
VEGF levels in the BAL fluid or the pleural effusion. The
relative contribution of local VEGF production in pneumo-
nia and also in the parapneumonic effusion is not well known.
It was reported that local production is the main source of
VEGF in the effusions rather than diffusion from the serum
(6) and VEGF is likely to originate from multiple cellular
sources such as the residential mesothelial cells, the circulat-
ing inflammatory cells, and the infiltrating malignant cells
within the pleural space (28). There was the correlation of
VEGF with the monocyte and macrophage concentrations
(29). It is thought that during acute infection such as bacte-
rial pneumonia, the blood supply increases as the inflamma-
tion progresses and the inflammatory cells infiltrate into the
inflamed tissue. As a result of the local VEGF production by
the recruited inflammatory cells, as well as the VEGF pro-
duction from the pulmonary epithelial cells, the endothelial
cells and the smooth muscle cells, the vascular permeability
increased; this in turn causes pulmonary edema or effusion.
In the systemic circulation, these inflammatory cells produce
VEGF, and this causes the elevation of the serum VEGF levels
as well.
In this study, serum VEGF levels increased significantly
in the patients with pneumonia compared to the controls,
especially in those patients with lobar pneumonia compared
to those patients with bronchopneumonia. For the patients
with lobar pneumonia, those patients with parapneumonic
effusion showed higher levels of serum VEGF compared to
the patients without effusion, and the children with a positive
urinary S. pneumoniae antigen test showed higher concentra-
tions of serum VEGF compared to those with negative results.
VEGF may be one of the key mediators that lead to more
severe and complicated pneumonia; this can provide resear-
chers with a new strategy for therapy in the future and so help
in the prevention of severe and complicated pneumonia.
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